Acrónimos


Acrónimo Significado

3Mdiet tres ingestas diarias
6Mdiet seis pequeñas ingestas
AAS Ácido Acetil Salicílico
AACE/ACE American Association of Clinical Endocrinologists/American College of Endocrinology
ACC American College of Cardiology
ACCORD Action to Control Cardiovascular Risk in Diabetes Trial. 
ACCORD-BP Action to Control Cardiovascular Risk in Diabetes- Blood Pressure
ACCORD-ION Action to Control Cardiovascular Risk in Diabetes  Follow ON
ACE2 Angiotensin-Converting Enzyme 2  o enzima convertidora de la angiotensina 2
ACG AutoControl de Glucemia
ACLS Aerobics Center Longitudinal Study
ACR Aptitud CardiorRespiratoria
ActRII receptor II de la activina tipo II
ACV Accidente CerebroVascular
ADA American Diabetes Association
ADAPTABLE Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness
ADDITION-Cambridge Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in PrimaryCare
ADH Alcohol DesHidrogenasa
ADNI AntiDiabéticos No Insulínicos
ADOPT Diabetes Outcome Progression Trial
ADRR Average Daily Risk Range
ADVANCE Action in Diabetes and Vascular Disease Study
ADVANCE-BP Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation  Blood Pressure
ADVANCE-ON Action in Diabetes and Vascular Disease Study-Observational Study
AEI Amputaciones Extremidades Inferiores
AFFIRM-AHF Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure
AGREE II Appraisal of Guidelines Research and Evaluation (second version)
AHA American Heart Association
AHEAD Action for Health in Diabetes (Look AHEAD)
AHEI Alternate Healthy Eating Index
AHRE episodio auricular de frecuencia alta
AHRQ Agencia para la Investigación y Calidad de la Atención Médica
AHS-2 Adventist Health Study-2
AI Auricula Izquierda.
aINS análogo de INSulina
AL Acidosis Láctica
ALA ácido alpha linoleico
ALLHAT-LLT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
AMPA Automedida domiciliaria de la Presión Arterial. 
AMPLITUDE-O First Results of the Effect of Efpeglenatide on Cardiovascular Outcomes
ANEMC Antagonistas No-Esteroideo del receptor MineralCorticoide
ANGII Angiotensina II
AP Atención Primaria
ApCV aptitud cardiovascular
APEI Amputación Extremidad Inferior
APP Arteriopatía Periferica
APPADL Ability to Perform Physical Activities of Daily Living Questionnaire (capacidad para realizar actividades físicas de la vida diaria)
ARA2 Antagonistas de los Receptores de la angiotensina II
arGLP-1 Análogos del receptor del péptido-1 similar al glucagón
ARIC Atherosclerosis Risk in Communities
ARNI inhibidores de la neprilisina
ARRIVE Aspirin to Reduce Risk of Initial Vascular Events
ARST Mineralocorticoid Receptor Antagonist Tolerability Study
ARST-DN Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy
ARST-HF Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure
ASCEND A Study of Cardiovascular Events in Diabetes
ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial
ASPREE Aspirin in Reducing Events in the Elderly
ATC Antithrombotic Trialists’ Collaboration
ATP  Adenosine TriPhosphato
ATP III Adult Treatment Panel III
AUC Área bajo la Curva
BA Bebidas Azucaradas
BARI-2D Bypass Angioplasty Revascularization Investigation 2 Diabetes
BBs Betabloqueantes
BES Binge Eating Scale
BPD Derivación BilioPancreática
BRACE CORONA Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among patients hospitalized with coronavirus disease 2019 (COVID-19) infection
BSRAA Bloqueo del Sistema Renina-Angiotensina-Aldosterona
B/F Bacteroidetes-to-Firmicutes ratio
CAC Cociente Albumina-Creatinina
CaCo Cancer de Colon
CAD Cetoacidosis diabética
CANVAS Canagliflozin Cardiovascular Assessment Study
CANTAYA-SU Canagliflozin _treatment and Trial Analysis-Sulfonylurea
CARDIA Coronary Artery Risk Development in Young Adults
CARE Consultation And Relational Empathy
CARMELINA Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus
CAROLINA CARdiovascular Outcomestudy of LINAgliptin versus glimepiride in patientswithtype 2 diabetes
CASCADE CArdiovaSCulAr Diabetes & Ethanol
CB Cirugía Bariátrica
CC Circunferencia de Cintura
CCAA Comunidades Autonomas
CCS Canadian Cardiovascular Society
CDA Canadian Diabetes Association.
CDC Centers for Disease Control and Prevention
CDM Core Diabetes Model
CGM Continuous Glucose Monitoring
CHANCES Consortium on Healthand Ageing Network of Cohorts in Europe and the United State
CHARM Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity
CHARM-ALTERNATIVE Candesartan in Heart Failure. Assess of Reduction in Mortality & Morbidity.
CHARM-PRESERVED Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
CHESS COVID-19 Hospitalisation in England Surveillance System
CHS Cardiovascular Health Study
CI Cardiopatia Isquémica
CINAHL Cumulative Index to Nursing and Allied Health Literature
CK-MB creatinina cinasa, isoenzima específica del miocardio.
CKD-EPI Chronic Kidney Disease Epidemiology
CKD273 Chronic kidney disease 273
CM Cirugía Metabólica
CMD CardioMiopatía Diabética
CMDB Conjunto Mínimo de Datos Básicos
CMS Centers for Medicare & Medicaid Services
CoefV Coeficiente de Variación
CONGA Continuous Overlapping Net Glycemic Action
CONSORT Consolidated Standards of Reporting Trials
Cor-SARS-2 Coronavirus–Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes Outcomes
CORONADO Coronavirus Disease and Diabetes Outcome
CoV Coronavirus   
COVID19 Coronavirus Disease 2019
CPRD Clinical Practice Research Database
CREDENCE Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
CV CardioVascular
CVD-REAL Comparative  Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
D2d Vitamin D and Type 2 Diabetes
DAPA-CKD Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
DAPA-FH Dapagliflozina y Prevención de Resultados Adversos en la Insuficiencia Cardíaca
DARE-19 Dapagliflozin in Respiratory Failure in Patients With COVID-19
DARWIN-T2D DAta for Real World evIdeNce in Type 2 Diabetes
DASH diet Dietary Approaches to Stop Hypertension
DAWN Diabetes Attitudes, Wishes and Needs
DAWN2 Diabetes Attitudes, Wishes and Needs 2 (segunda edición)
DBHC Dieta Baja en Hidratos de Carbono
DCCT Diabetes Control and Complications Trial. 
DE Desviación Estandar
DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58
DEFINE-HF Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction
DEG-100 Degludec 100 UI
DELIVER Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure
DESIR Epidemiological Study on the Insulin Resistance  Syndrome
DET Diferencia Estimada del Tratamiento
DFF Dosis Fija de Farmacos
DG Diabetes Gestacional
DHC Dieta HipoCalórica
DiRECT Diabetes Remission Clinical Trial
DISCOVER DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DM Diabetes Mellitus. 
DM1 Diabetes tipo 1
DM2 Diabetes Mellitus tipo 2
DMBHC Dieta Muy Baja en Hidratos de Carbono
DME Diferencia Media Estandarizada
DMP Diferencia Media Monderada
DMR Dispositivo de Monitorización Remota
DPAIB Diferencias en la PA entre los brazos
DPP Diabetes Prevention Program
DPPOS Diabetes Prevention Program Outcomes Study
DREAM Diabetes Reduction Assessment with ramipril and rosiglitazone Medication
DS Desviación Estandar
DSM-5 Diagnostic and Statistical Manual of Mental Disorders 5
DSMES Educación y el Apoyo para el Autocontrol de la Diabetes
DT Diferencias de Tasas
DTSQ Satisfacción con el Tratamiento de la Diabetes
DTSQc Satisfacción con el Tratamiento de la Diabetes  y cambio
EA Efecto Adverso
EAG Efecto Adverso Grave
EAS European Atherosclerosis Society
EASD European Association for the Study of Diabetes
EASEL Evidence for Cardiovascular Outcomes With Sodium Glucose Cotrnasporter 2 Inhibitors in the Real Word
ECA Ensayo Clinico Aleatorizado
ECANICV Ensayos Clínicos Aleatorizados de No Inferioridad CardioVascular
ECC Evento Coronario
ECG Electrocardiograma.
ECV Enfermedad CardioVascular
ECVa Enfermedad Cardiovascular Arteriosclerótica
EDIC Epidemiology of Diabetes Interventions and Complications
EDRFA Encuestas Dietéticas Retrospectivas de Frecuencia Alimentaria
EDWPOP European Diabetes Working Party for Older People
EFA Entrenamiento Físico Aeróbico
eFI Frailty Index
EGIR European Group for the study of Insulin Resistence 
EH Estancia Hospitalaria
ELIXA Evaluation of  LIXisenatide in Acute Coronary Syndrome
EMD Edema Macular Diabético
EMA Agencia Europea de Medicamentos
EMDAC Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)
EMPA-HEART CardioLink-6 Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes  Cardiolink-6
EMPA-KIDNEY The Study of Heart and Kidney Protection With Empagliflozin
EMPA-REG OUTCOME Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose
EMPA-TROPISM Safety and Efficacy of Empagliflozin versus Placebo on Top of Guideline-directed Medical Therapy in Heart Failure Patients with Reduced Ejection Fraction without Diabetes
EMPEROR-Preserved EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction 
EMPEROR Pooled EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure pooled
EMPEROR-Reduced EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction
EMPRISE EMPagliflozin compaRative effectIveness  and SafEty
EN Emociones Negativas
EPA ácido eicosapentaenoico
EPIC European Prospective Investigation of Cancer
EPIDIAR Epidemiología de la DIABETES y el Ramadán
EPO Eritropoyetina
EQ-5D-3L European Quality of Life-5 Dimensions -3Life
EQA Estandar de Calidad Asistencial
ER Ejercicio de Resistencia
ERA Enfermedad Renal Aguda
ERC Enfermedad Renal Crónica
ERFC Emerging Risk Factor Collaboration
ERT Enfermedad Renal Terminal
erMedDiet Dieta Mediterranea energéticamente restrictiva
ES Endocrine Society
ESC European Society of Cardiology
ESCADIANE Estudio sobre las características de los pacientes ancianos con diabetes en España
ESD Efectos Secundarios aDversos
ETDRS Early Treatment Diabetic Retinopathy Study
EvCV Evento CardioVascular
EV Estilos de Vida
EXAMINE Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
EXSCEL Exenatide Study of Cardiovascular Event Lowering
FAERS FDA’s Adverse Event Reporting System
FAH Falta de AdHerencia
FANV Fibrilación Auricular No Valvular
FDA Food Drug Administration
FDC Fixed-dose combination (FDC)
FDPS Finnish Diabetes Prevention Study
FE Fracción de Eyección 
FEVI Fracción de Eyección del Ventrículo Izquierdo
FFQ Food Frequency Questionnaire
FGe Tasa de Filtración Glomerular estimada
FGm FGe media
FHS Framingham Heart Study
FIGHT Functional Impact of GLP-1 for Heart Failure Treatment
FIGARO-DKD Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
FIDELIO-DKD Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
FIDELITY Finerenone Cuts CV Risk in T2D Across CKD Spectrum
FO Fondo de Ojo
FORCE Fatty Acids and Outcomes Research Consortium
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
FRCM Factor de Riesgo CardioMetabólico
FRCV Factor de Riesgo Cardiovascular
FSH Hormona Estimulante del Folículo
GAD65 Ácido Glutámico Decarboxilasa 65
GALACTIC-HF Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure
GB Glucosa Basal
GBA Glucosa Basal Alterada.
GEDAPS Grupo de Estudio para la Diabetes en Atención Primaria de Salud.
GIN Guidelines International Network
GLA-300 Glargina 300 UI
GLY Gliburide
GoDARTS Observacional Genetics of Diabetes Audit and Research in Tayside Scotland
GPC Guía de Práctica Clínica
GRADE study Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
GRADE Grading of Recommendations Assessment, Development, and Evaluation
GPRD General Practice Research Database 
GTHS Globulina Transportadora de las Hormonas Sexuales
GTZ Glitazonas (Tiazolidinedionas)
HARPdoc Hypoglycaemia Awareness Restoration Programme
HARMONY Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease
HbA1c Hemoglobina glicada, glucada o Glucohemoglobina.
HC Hidratos de Carbono
HCQ HidroxiCloroQuina
HDL-c colesterol ligado a lipoproteínas de alta densidad
hdPS high-dimensional propensity score
HF-ACTION Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training
HFSA Heart Failure Society of American
HGI Hemorragia GastroIntestinal
HH Hiperglucemia Hiperosmolar
HI Hiperinsulinemia.
HIC Hospitalización por Insuficiencia Cardiaca
HOMA2 B Homeostasis de la célula B pancreática
HOMA2 IR Homeostasis insulinarresistencia
HOPE Heart Outcomes Prevention Evaluation
HOT Hypertension Optimal Treatment 
HPFS Health Professionals Follow-up Study
HR Hazard Ratio
HRS Health and Retirement Study
hs-TnT Troponina T ultrasensible
I/E criterios de inclusión/exclusión
I-PRESERVED Irbesartan in Heart Failure with Preserved Ejection Fraction Study
I2 Heterogenicidad sustancial
IA Inteligencia Artificial
IA2 antígeno de los islotes 2
IADPSG International Association of the Diabetes and Pregnancy Study Groups
IAGG International Association of Gerontology and Geriatrics
IAM Infarto Agudo de Miocardio
IBP Inhibidor de la Bomba de Protones
IC Insuficiencia Cardiaca
IC 95% Intervalo de Confianza del 95%
ICA512 autoantígeno de células de los islotes 512
ICC Insuficiencia Cardíaca Congestiva
ICCa Indice cintura/cadera
ICE Indice cintura/estatura
ICFEP IC con fracción de eyección preservada
ICFER IC con fracción de eyección reducida
ICFErec IC con fracción de eyección del Ventriculo Izquierdo recuperada
ICi intervalo de confianza incierto
ICL Inercia Clínica
ICS Instituto Catalá de la Salud
ICSI Institute for Clinical Systems Improvement
ICT Indice CardioTorácico.
IDF International Diabetes Federation. 
iDPP4 Inhibidores de la dipeptidilpeptidasa 4 
IECA inhibidores de la enzima conversora de la angiotensina.
IEV Intervencion en Estilos de Vida
IG Índice Glucémico
IGLA Insulina glargina
IL Interleucina o InterleuKina
IMC Indice de masa corporal. 
IMCMD IMC mayor antes del debut de la DM2
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial
IMVI índice de masa del VI
InCC índice de depósito Cálcico Coronario
INRA Inhibidores de la Neprilisina y de los  Receptores de Angiotensina 2
INS Insulina
INSAL Análogos de insulina prolongada
INSB Insulina Basal
INS DEGL Insulina Degludec
INSG Insulina Glargina
INSIGHT Intervention as a Goal in Hypertension Treatment
IPAQ-SF Physical Activity Questionnaire Short Form
IPC índice de peptido C
IPE etil icosapenteno
IPTW sistema de ponderamiento de la posibilidad tratamiento inverso
IQR Rango Interquartil
IRC Insuficiencia Renal Crónica
IRD Diabetes relacionada con la herencia
IRIS Insulin Resistance Intervention after Stroke
IRR incidence rate ratio
iSGLT2 Inhibidores del cotransportador de sodio-glucosa 2
ISO Organización Internacional de Normalización
IT Inercia Terapéutica
ITG Intolerancia a la glucosa
IW-SP Impact of Weight on Self-Perceptions (Impacto del peso sobre la autopercepción)
IWGDF International Working Group on the Diabetic Foot
JHU Johns Hopkins University
JUPITER Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
K+ Potasio
KCCQ Kansas City Cardiomyopathy Questionnaire
KCCQ-CS Kansas City Cardiomyopathy Questionnaire Clinical summary Score
KDIGO Kidney Disease: Improving Global Outcomes
KPNC Kaiser Permanente Northern California
LAGB técnica de una banda gástrica laparoscópica
LDL-col low-density lipoprotein (Lipoproteina de baja densidad)-colesterol
LEADER Liraglutide Effect and Action in Diabetes: Evaluation of  cardiovascular Outcome Results
LEAN Liraglutide Safety and Efficacy in Patients with NASH
LFC Liver Fat Content
LH Hormona Luteinizante
LIBERATES Improving Glucose Control in Patients With Diabetes Following Myocardial Infarction: The Role of a Novel Glycaemic Monitoring
LINA Linagliptina
LPIR resistencia lipoprotéica a la insulina
LST Life`s Simple 7
LTC Centros de Atención a largo plazo
MACE Major Adverse Cardiovascular Events (eventos adversos cardiovasculares mayores)
MAGE amplitud media de las excursiones glucémicas
MALE Major Adverse Limb Events (Efectos adversos mayores en las extremidades)
MAPA Monitorización Ambulatoria de la Presión Arterial.
MARD Diabetes leve relacionada con la edad
MBE Metodología Basada en la Evidencia  o Medicina Basada en la Evidencia
MCC Muerte por Cualquier Causa
MCP-1 proteína quimiotáctica de monocitos tipo 1
MCV Muerte de causa CardioVascular
MD Mediana de Diferencia de medias
MDRD Modification of Diet in Renal Disease
MEASURE-HF Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
MedDiet Dieta Mediterránea
MERS Síndrome Respiratorio de Medio Oriente
MERS-CoV Middle East Respiratory Syndrome-related CoronaVirus
MesH Medical Subject Headings
MET Metformina
MEV Modificación de Estilos de Vida
MFR Multiples Factores de Riesgo
MGC Masa grasa Corporal
MM Masa Magra
MMSE Mini-Mental State Examination
MNA Mini Nutritional Assessment
MOD Diabetes relacionada con la obesidad
MODY Maturity-Onset Diabetes of the Young
MRAS antagonistas de los receptores mineralocorticoides
MSC Ministerio de Sanidad y Consumo
MTP Medicamento Tradicional a base de Plantas
MUFA Mono- Unsaturated Fatty Acids
MUST Malnutrition Universal Screening Tool
n número 
N Engl J Me New England Journal of Medicine
Na Sodio
NA Neuropatía Autonómica
NAC Neuropati Autonómica Cardíaca
NAFLD Non-Alcoholic Fatty Liver Disease (esteatosis hepática no alcohólica)
NASH Non-Alcoholic SteatoHepatitis (esteatohepatitis no alcohólica)
NCCMERP National Coordinating Council for Medication Error Reporting and Prevention.
NCD RisC NCD Risk Factor Collaboration
NCEP US National Cholesterol Education Programme. 
NDA National Diabetes Audit
NDDG National Diabetes Data Group
NDEP National Diabetes Education Program
NDIT Neuropatia Diabética Inducida por el Tratamiento
NDM Nefropatia Diabética
NDMA N_Nitrosodimetilamina
NESDA Netherlands Study of Depression and Anxiety
NGC National Guidelines Clearinghouse
NGSP National Glycohemoglobin Standardization Program. 
NHANES National Health and Nutrition Examination Survey
NHMRC Australian Government National Health and Medical Research Council
NICE National Institute for Clinical Excellence. 
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
NIH National Institutes of Health
NIS Nationwide Inpatient Sample
NMA Network-Meta Analysis
NNH Número necesario a tratar para producir un evento adverso
NNT Número Necesario a Tratar
NNT10 NNT en 10 años
NNTT Nuevas Tecnologias
NPD Neuropatía diabética
NPDP Neuropatía diabética Periférica
NT-proBNP fracción N terminal de la prohormona del peptido natriurético cerebral
NU-AGE New dietary strategies addressing the specific needs of elderly population for an healthy ageing in Europe
NYHA New York Heart Association
OBSERVE-4D A real-world meta-analysis of 4 observational databases
ODYSSEY OUTCOMES Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
OECD Organisation for Economic Co-operation and Development
OMD Osteomielitis
OMS Organización Mundial de la Salud
ON Óxido Nítrico
ONCE Organización Nacional de Ciegos de España
ONS Office for National Statistics
OPG OsteoProteGerina
OPN OsteoPoNtina
OR odds ratio
OVR Oclusion de la Vena Retiniana
PA Presión Arterial
PAD Presión Arterial Diastólica
PARADIGM-HF Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
PARADISE´MI Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction
PARAGON Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction
PARALLAX A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
PAS Presión Arterial Sistólica
PC Perímetro de Cintura
PCDE Primary Care Diabetes Eurrope
PCI Práctica Colaborativa Interprofesional
PCORnet National Patient-Centered Clinical Research Network
PCR prueba de reacción en cadena de la polimerasa
PCS ProCalcitonina Sérica
PCSK9 Proprotein Convertasa Subtilisin Kexin 9
PCV13 Polisacaridos conjugada  valente 13
PDA Polish Diabetes Association
PDC Proporción de Días Cubiertos
PDM Pie Diabético
PEP-CHF Perindopril in Elderly People with Chronic Heart Failure
PERCEDIME Prevalencia de la Enfermedad Renal  Crónica En pacientes con DIabetes MEllitus  tipo 2 en las consultas de atención primaria
PGA Perfil Glucémico Ambulatorio
PHQ-9 Patient Health Questionnaire-9
PIO Pioglitazona
PIONEER Peptide InnOvatioN for Early DiabEtes TReatment
PP Prevencion Primaria
PPROMs Patient reported outcome measures
PPSV23 Vacuna Neumocócica de polisacáridos 23 valente
PPSDiab post gestational diabetes study
PRED PREDiabetes 
PREDAPS PREDiabetes en Atención Primaria de Salud (Primary Health Care on the Evolution of Patients with Prediabetes )
PREDIM índice de evaluación de la homeostasis y la sensibilidad a la INS
PREDIMED PREvención con DIeta MEDiterránea
PREDIMED-PLUS PREvención con DIeta MEDiterránea-Plus
PRESERVED-HF Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
PRIORITY Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events 
PROSPER Pravastatin in elderly individuals at risk of vascular disease
PRR tasa proporcionales por año
PS Propensity scores (puntaje por propensión)
PTH Paratohormona
PUFA Poly- Unsaturated Fatty Acids
PY persona/año (PY)
QALYs años de vida ajustados por calidad neta
RAMQ Régie de l’assurance maladie du Québec
RAP Riesgo Atribuible Poblacional
RCV Riesgo CardioVascular
RD reducción de riesgo
RedGDPS Red de Estudios de la Diabetes en Atención Primaria de la Salud
RECORD Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes
RECORD-PE The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology
REDUCE-IT Reduction of Cardiovascular Events with EPA-Intervention Trial
ReFLeCT Results From Real-World Clinical Treatment With Tresiba®
REGARDS Reasons for Geographic and Racial Differences in Stroke
REGICOR Registre Gironí del Cor
REHAB-HF REhabilitation Therapy in Older Acute Heart Failure Patients
RESPECT-EPA Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid)
REWIND Researching cardiovascular Events with a Weekly INcretin in Diabetes
RI Resistencia a la insulina.
RIGHT Reporting Items for Practice Guidelines in Healthcare
RISE Restoring Insulin Secretion
RNM Resonancia Nuclear Magnética
RNM-PDFF Resonancia  Nuclear Magnética  – Proton Density Fat Fraction
RMNC Resonancia Magnética Nuclear Cardíaca
RNAO Registered Nurses' Association of Ontario
ROCKET AF Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
ROSE The Retrospective Study of Cardiovascular Events Related to the Use of Glucose-Lowering Drug Treatment in Primary Care
ROSG Rosiglitazona
RPM Ratio de posesión de medicamentos
RRI Respuesta rápida de la Insulina
RRR Reducción del Riesgo Relativo
RT-PCR Reverse Transcriptase Polymerase Chain Reaction (reacción en cadena de la polimerasa con transcripción inversa)
rtCGM real-time continuous glucose monitoring (monitorización continua de glucosa en tiempo real)
RTDM Retinopatia Diabética
RTDML Retinopatia Diabética Leve
RTDMNP Retinopatia Diabética No Proliferativa
RTDMP Retinopatia Diabética Proliferativa
RWD Real World Evidence (datos de la vida real)
RYGB técnica de bypas en Y de Roux
S/V Sacabutril/Valsartan
SAID Diabetes Autoinmunidad Severa
SAHOS Síndrome de Apnea hipopnea Obstructiva del Suaño
SAVOR-TIMI Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction
SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
SEARCH SEARCH for Diabetes in Youth
SEMA Semaglutide
SF-36 Short Form 36
SIDD Diabetes con deficiencia severa de insulina
SIDIACO-RETRO Sitagliptin Treatment in Diabetic COVID-19 Positive Patients
SIDIAP Spanish Information System for the Development of Research in Primary Care
SIGN Scottish Intercollegiate Guidelines Network
SIRD Diabetes con resistencia grave a la Insulina
SMBG Sistema de Monitorización de Glucosa Basal
SMC Standars of Medical Care
SMCG Sistema de Monitorización Continua de Glucosa
SMS Servicio de Mensajes Simples
SNP nucleótidos de un solo polimorfismo
SNS Sistema Nacional de Salud
SOG Prueba de Sobrecarga o tolerancia oral a la glucosa. 
SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure
SOPQ Síndrome de Ovario Poliquistico
SOS Swedish Obese Subjects  (Sujetos Obesos Suecos)
SOTA Sotagliflocina
SOUL A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
SOURMOUNT Study of Tirzepatide in Participants With Obesity or Overweight)
SPD Sistema Personalizado de Dosificación
SPPB Short Physical Performance Battery (Bateria de rendimiento físico corto)
SPRINT Systolic Blood Pressure Intervention Trial
SRAS  Síndrome Respiratorio Agudo Severo
SRAS-CoV-2 Síndrome Respiratorio Agudo Severo por CoronaVirus 2 
SRDA Sindrome de Distres Respiratorio Agudo
SSE Situación SocioEconómica
sST2 péptido factor de tumorogenicidad soluble de tipo 2
STAMPEDE Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently
STAREE Statins for Reducing Events in the Elderly
STENO 2 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. 
STEP 1 Semaglutide Treatment Effect in People with obesity
STITCH Simplified Treatment Intervention to Control Hypertension
STRENGTH Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia
STROBE Strengthening of Reporting of Observational Studies in Epidemiology
SUGAR-DM-HF StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus and Heart Failure
SURDIAGENE Suivi Rénal, DIAbète de type 2 et GENEtique
SURPASS Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
SURPASS-3 CGM SURPASS-3 Continuous Glucose Monitoring
SURPASS MRI SURPASS Magnetic Resonance Imaging
SUSTAIN Semaglutide in Subjects with Type 2 Diabetes
T1D-GRS puntaje de riesgo genómico de la DM1
TCH Texas Children’s Hospital
TDO Terapia Directamente Observada
TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin
TEP Tromboembolismo Pulmonar
TER Tiempo en Rango Glucemico
THEMIS Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
THIN The Health Improvement Network
TIPS-3 The International Polycap Study 3
TMPRRSS2 Transmembrane Serine Protease 2 o Proteasa Transmembrana Serina 2
TODAY Treatment Options for type 2 Diabetes in Adolescents and Youth
TOHB Terapia con Oxígeno HiperBárico
TOPCAT Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist
TOSCA IT Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial
TPP Tasa de Participación en la Prevalencia
TriMASTER 3-way cross-over trial of precision medicine strategy of 2nd/3rd line therapy in type 2 diabetes
TRIUMPH Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension
TRS Terapia Renal Sustitutiva
TSMR Tiempo de supervivencia media restringida
TVP Trombosis Venosa Profunda
TZP Tirzepatida
UAB University of Alabama at Birmingham
UARD Diabetes relacionado con ácido úrico
UCI Unidad de Cuidados Intensivos.
UD Úlcera diabética
UDP Úlcera diabética en el pie
UKB UK Biobank
UKPDS United Kingdom Prospective Diabetes Study Group.
USPSTF US Preventive Services Task Force
VA Veterans Affairs
VADT Veterans Affairs Diabetes Trial
VD Ventrículo derecho.
VEGF Vascular Endothelial Growth Factor  o factores de inhibición del crecimiento vasculo-endotelial
VERIFY Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes
VERTIS CV eValuation of ERTugliflozin effIcacy and Safety CardioVascular
VFC Variabilidad de la Frecuencia Cardiaca
VHA Veterans Health Administration
VI Ventrículo izquierdo.
VICTORIA VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction
VITAL VITamin D and OmegA-3 Tria
VIVIDD Vildagliptin in Ventricular Dysfunction Diabetes
VLDL-col Lipoproteina de muy baja densidad-colesterol
VMI Ventilación Mecánica Invasiva
VMR Variabilidad Media Real
VN Vacuna antiNeumocócica
WESDR Wisconsin Epidemiologic Study of Diabetic Retinopathy
WHI Women’s Health Initiative
WHS Wound Healing Society
WHS Women´s Health Study
ZnT8 antigeno del trasportador de Zinc 8
Recursos en internet
Diccionario de Siglas Médicas http://www.sedom.es/diccionario/
RAE https://dle.rae.es/

No hay comentarios: